Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 3Active not recruiting 3Completed 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 17Ovarian Neoplasms 12Neoplasms 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Neoplasm Metastasis 6Endometrial Neoplasms 4Neuroendocrine Tumors 3Glioma 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Recurrence 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Fanconi Anemia, Complementation Group D1 2Cholangiocarcinoma 2Uveal Melanoma 1Urogenital Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1SCLC,Extensive Stage 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Platinum-sensitive Ovarian Cancer 1

Interventions

Magnetic Resonance Spectroscopy 20Temozolomide 16Radiotherapy 10Specimen Handling 7Blood Specimen Collection 7Radiation 6Bevacizumab 5Nivolumab 4Cyclophosphamide 4Biopsy 4vorasidenib 3trametinib 3pembrolizumab 3olaparib 3fludarabine 3dabrafenib 3Watchful Waiting 3Surgical Procedures, Operative 3Magnetic Resonance Imaging 3Drug Therapy 3olutasidenib 2lutetium Lu 177 dotatate 2fluorodopa F 18 2fluciclovine F-18 2entrectinib 2contrast agent BR1 2X-Rays 2Restraint, Physical 2Radiosurgery 2Microdialysis 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Glioma × olaparib × Clear all
NCT06607692 2026-04-14

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
57 enrolled
CNS

Glioma

NCT03991832 2024-07-18

SOLID

University Health Network, Toronto

Phase 2 Recruiting
58 enrolled
CNSGastrointestinal

Glioma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡